Recent Updates
Recently added Catalysts
MIRA Positive Sentiment

MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN

Wednesday, May 27, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: MIRA Pharmaceuticals has secured worldwide rights for Ketamir-2, enhancing its intellectual property portfolio across 10 major markets. This move is expected to provide the company with increased strategic flexibility and potential long-term value. The announcement comes ahead of the Phase 2a clinical trial for the treatment of chemotherapy-induced peripheral neuropathy (CIPN).
Price reaction · baseline $0.974 (2026-05-26 close) · hit pre-market · clean, no other MIRA news in the window
day 0 close · peak
+18.6%
day 1
+10.9%
day 3
+7.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • MIRA Pharmaceuticals expands its global IP portfolio.
  • Secured rights for Ketamir-2 across 10 major markets.
  • Enhances strategic flexibility and long-term value potential.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+5%
120-day peak, hindsight
Typical move
0.6%
average across 2 past catalysts
Cash runway
~21 mo
Low dilution risk

Full Press Release Details

Expanded Global Intellectual Property Portfolio Enhances Strategic Flexibility and Long-Term Value Potential for Ketamir-2 MIAMI, FL / ACCESS Newswire / May 27, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA” or the “Company”) , a clinical-stage pharmaceutical company focused on the development of proprietary therapeutics for neurologic, neuropsychiatric, inflammatory, and metabolic disorders, today announced the execution of Amendment No. 1 to its exclusive Ketamir-2 license…
You can read the full content here

Frequently Asked Questions

What is Ketamir-2?

Ketamir-2 is a therapeutic candidate developed by MIRA Pharmaceuticals for treating various disorders.

What markets does MIRA expand into?

MIRA Pharmaceuticals expands its IP portfolio across 10 major global markets.

What is the significance of the IP expansion?

The expansion enhances MIRA's strategic flexibility and potential long-term value.

What trial is MIRA preparing for?

MIRA is preparing for a Phase 2a clinical trial for Ketamir-2 in chemotherapy-induced peripheral neuropathy.

ShareAdd on Google
Tags: MIRA Viatris Investor Conferences Healthcare MIRA Pharmaceuticals Ketamir-2 CIPN global IP portfolio clinical-stage
Last updated: May 27, 2026

Biotech snapshot

Cash runway
$9M liquidity · $0M/mo burn
~21 mo
Low dilution risk

Catalyst track record

+5%
best trade around MIRA's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for MIRA.

See every catalyst's timing & PoA →